Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Withdrawal of off-label antipsychotics in adults with intellectual disabilities
NL-OMON21687Recruiting
- Sponsor
- Erasmus MC
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of risperidone and pipamperone in behavioral disorder and intellectual disability (ID) (2 arms), sponsored by Erasmus MC. Primary endpoint: Protocol completion rate. Started Mar 2019; status: recruiting.
02
Drugs
risperidonepipamperone
03
Conditions
behavioral disorderintellectual disability (ID)
Beyond the preview
Go deeper on NL-OMON21687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21687.